



# Global Pharmaceutical Companies Executive Survey 2017: Profiles and Financial Data

*Wiseguyreports.com Announces the Publication of its Research Report – GLOBAL Pharmaceutical Companies Market 2017*

PUNE, INDIA, April 20, 2017 /EINPresswire.com/ -- [Pharmaceutical Companies Industry](#)

Latest Report on Pharmaceutical Companies Market Global Analysis & 2022 Forecast Research Study

With growing Chinese economy and increasing residents' income, people's purchasing power of pharmaceuticals has been enhanced. China's aging population also promotes demand for pharmaceuticals. In 2016, revenues from main businesses of China's pharmaceutical industry reached CNY 2,963.59 billion, up by 9.9% YOY; profits were CNY 321.64 billion, up by 15.6% YOY. Among sub-industries, active pharmaceutical ingredients (API), pharmaceutical preparations and medical devices maintained strong profitability, witnessing their profits grow by 25.9%, 16.8% and 32.3%, respectively. The revenues from main businesses of pharmaceutical preparations, TCM decoction pieces processing, sanitary materials & medical products and medical devices industries were higher than average and grew by 10.8%, 12.7%, 11.5% and 13.3%, respectively.

Try Sample Report @ <https://www.wiseguyreports.com/sample-request/1201815-a-share-listed-pharmaceutical-companies-profiles-and-financial-data>

In 2016, the revenue of the chemical pharmaceutical industry reached CNY 1,256.96 billion, up by 9.9% YOY; profits were CNY 139.57 billion, up by 19.6% YOY; export delivery value was CNY 79.26 billion, up by 4.5% YOY. The operating revenue of API manufacturers totaled to CNY 503.49 billion, up by 8.4% YOY; profits were CNY 44.53 billion, up by 25.9% YOY; export delivery value was CNY 64.87 billion, up by 7.4% YOY.

CRI expects that in the next few years, demand for pharmaceuticals will rise with increasing residents' income, upgrading consumption, aging population, accelerating urbanization and improving healthcare system, promoting the development of China's pharmaceutical industry. In this report, CRI analyzes 161 pharmaceutical enterprises listed in A-share market in China.

The report is composed of two parts: the first part is enterprise profiles and the second part is the operation status of these enterprises in the recent decade (presently 2006 to 2016, we will

update it to the latest as time goes by).

The operation status is demonstrated from the following perspectives: (1) financial indexes, such as earnings per share, book value per share (BPS), sales per share, net cash flow per share, return on net worth and debt to asset ratio; (2) indexes on the income statement, such as revenue, operating profit, net profit and EBIT; (3) indexes on the income statement, such as revenue, operating profit, net profit and EBIT; (4) indexes on the balance sheet, such as liquid asset, fixed asset, current liability, non-current liability, capital reserve and shareholders' equity.

For Detailed Reading Please visit WiseGuy Reports @

<https://www.wiseguyreports.com/reports/1201815-a-share-listed-pharmaceutical-companies-profiles-and-financial-data>

#### (1) Financial Indexes

- Earnings per Share
- Book Value per Share (BPS)
- Sales per Share (SPS)
- Net Cash Flow per Share from Operations
- Net Cash Flow per Share (CNY)
- Return on Net Worth
- Net Profit Margin on Total Assets
- Return on Invested Capital (ROIC) (%)
- Gross Profit Margin on Sales (%)
- Net Profit Margin on Sales (%)
- EBIT Margin (%)
- EBITDA Margin (%)
- Debt to Asset Ratio (%)
- Total Asset Turnover (times)
- Cash/Operating Income Received from Sales of Goods or Services
- YOY Growth Rate of Operating Revenue (%)
- YOY Growth Rate of Operating Profit (%)
- YOY Growth Rate of Net Profit Attributable to Shareholders of Parent Company (%)

#### (2) Summary of Income Statement

- Gross Revenue (CNY, million)
- Total Operating Costs (CNY, million)
- Revenue (CNY, million)
- Operating Profit (CNY, million)
- Total Profit (CNY, million)
- Net Profit (CNY, million)
- Net Profit Attributable to Shareholders of Parent Company (CNY, million)
- Non-recurring Items (CNY, million)
- Net Profit Deducting Non-recurring Items (CNY, million)

- R&D Costs (CNY, million)
- Earnings Before Interest and Tax (EBIT) (CNY, million)
- Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) (CNY, million)

If you have any enquiry before buying a copy of this report @

<https://www.wiseguyreports.com/enquiry/1201815-a-share-listed-pharmaceutical-companies-profiles-and-financial-data>

### (3) Summary of Balance Sheet

- Liquid Asset (CNY, million)
- Fixed Asset (CNY, million)
- Long-term Equity Investment
- Total Assets (CNY, million)
- Liquid Liability (CNY, million)
- Non-current Liability (CNY, million)
- Total Liability (CNY, million)
- Capital Reserve (CNY, million)
- Surplus Reserve (CNY, million)
- Undistributed Profit (CNY, million)
- Shareholders' Equity (CNY, million)
- Equity Attributable to Shareholders of Parent Company (CNY, million)

### (4) Summary of Cash Flow Statement

- Cash Received from Sales of Goods and Services (CNY, million)
- Cash Flow from Operations (CNY, million)
- Cash Paid to Purchase Fixed Assets, Intangible Assets and Other Long-term Assets (CNY, million)
  
- Cash Paid for Investments (CNY, million)
- Cash Flow from Investments (CNY, million)
- Cash Received from Investors (CNY, million)
- Cash Received from Borrowings (CNY, million)
- Cash Flow from Financing (CNY, million)
- Net Increase of Cash and Cash Equivalents (CNY, million)
- Cash and Cash Equivalents, End of Period (CNY, million)
- Depreciation and Amortization (CNY, million)

Some Major Points from Table of content:

Companies in the report:

- 1 Shenzhen Cau Technology Co., Ltd. (000004.SZ)
- 2 Anhui BBKA Pharmaceutical Co., Ltd. (000153.SZ)
- 3 Zhenxing Biopharmaceutical & Chemical Inc. (000403.SZ)
- 4 Dong-E-E-Jiao Co., Ltd. (000423.SZ)

- 5 Livzon Pharmaceutical Group Co., Ltd. (000513.SZ)
- 6 Jiangsu Sihuan Bioengineering Co., Ltd. (000518.SZ)
- 7 Yunnan Baiyao Group Co., Ltd. (000538.SZ)
- 8 Hainan Haiyao Co., Ltd. (000566.SZ)
- 9 Tus-Guhan Group Corp., Ltd. (000590.SZ)
- 10 Northeast Pharmaceutical Group Co., Ltd. (000597.SZ)
- 11 Shenzhou Yiqiao Information Service Co., Ltd. (000606.SZ)
- 12 Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ)
- 13 Renhe Pharmacy Co., Ltd. (000650.SZ)
- 14 Apelo Pharmaceutical Co., Ltd. (000739.SZ)
- 15 Shandong Xinhua Pharmaceutical Company Limited (000756.SZ)
- 16 Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (000766.SZ)
- 17 PKU Healthcare Corp., Ltd. (000788.SZ)
- 18 Chengdu Taihe Health Technology Group Inc., Ltd. (000790.SZ)
- 19 Dezhan Healthcare Company Limited (000813.SZ)
- 20 Hunan Jingfeng Pharmaceutical Co., Ltd. (000908.SZ)
- 21 Shandong Shanda Wit Science And Technology Co., Ltd. (000915.SZ)

Continued.....

For more information or any query mail at [sales@wiseguyreports.com](mailto:sales@wiseguyreports.com)

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/376970511>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.